Skip to main content
SpringerLink
Log in

Ivabradine: A Review of Labeled and Off-Label Uses

  • Review Article
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

Abstract

Ivabradine is a unique medication recently approved in the USA for the treatment of select heart failure patients. It was first approved for use in several countries around the world over a decade ago as an anti-anginal agent, with subsequent approval for use in heart failure patients. Since ivabradine has selective activity blocking the I f currents in the sinus node, it can reduce heart rate without appreciable effects on blood pressure. Given this heart-rate-specific effect, it has been investigated in many off-label indications as an alternative to traditional heart-rate-reducing medications such as beta blockers and calcium channel blockers. We conducted searches of PubMed and Google Scholar for ivabradine, heart failure, HFrEF, HFpEF, angina, coronary artery disease, inappropriate sinus tachycardia, postural orthostatic hypotension, coronary computed tomography angiography and atrial fibrillation. We reviewed and included studies, case reports, and case series published between 1980 and June 2016 if they provided information relevant to the practicing clinician. In many cases, larger clinical trials are needed to solidify the benefit of ivabradine, although studies indicate benefit in most therapeutic areas explored to date. The purpose of this paper is to review the current labeled and off-label uses of ivabradine, with a focus on clinical trial data.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Reproduced with permission from Canet et al. [3]

Similar content being viewed by others

References

  1. Speranza L, Franceschelli S, Riccioni G. The biological effects of ivabradine in cardiovascular disease. Molecules. 2012;17:4924–35.

    Article  CAS  PubMed  Google Scholar 

  2. Manza M, Reuter M, Lauck G, Omran H, Jung W. A single intravenous dose of ivabradine, a novel If inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology. 2003;100:149–55.

    Article  Google Scholar 

  3. Canet E, Lerebours G, Vilaine J-P. Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine. Ann N Y Acad Sci. 2011;1222:90–9.

    Article  CAS  PubMed  Google Scholar 

  4. Corlanor® [package insert]. Thousand Oaks, CA: Amgen Inc; 2015.

  5. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L on behalf of the SHIFT investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376:875–85.

  6. Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long-term prognostic value of resting heart rate in patients with suspected or proved coronary artery disease. Eur Heart J. 2005;26:967–74.

    Article  PubMed  Google Scholar 

  7. Swedberg K, Komajda M, Bohm M, Borer J, Robertson M, Tavazzi L, Ford I, for the SHIFT investigators. Effects of outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Findings from the SHIFT study. J Am Coll Cardiol. 2012;59:1938–45.

  8. Bocchi EA, Böhm M, Borer JS, Ford I, Komajda M, Swedberg K, Tavazzi L on behalf of SHIFT investigators. Effect of combining ivabradine and β-blockers: Focus on the use of carvedilol in the SHIFT population. Cardiology. 2015;131:218–24.

  9. Kosmala W, Holland DJ, Rojek A, Wright L, Przewlocka-Kosmala M, Marwick TH. Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2013;62(15):1330–8.

    Article  CAS  PubMed  Google Scholar 

  10. Volterrani M, Cice G, Caminiti G, Vitale C, D’Isa S, Perrone Filardi P, Acquistapace F, Marazzi G, Fini M, Rosano GM. Effect of carvedilol, ivabradine or their combination on exercise capacity in patients with heart failure (the CARVIVA HF trial). Int J Cardiol. 2011;151(2):218–24.

  11. Riccioni G, Masciocco L, Benvenuto A, Saracino P, De Viti D, Massari F, Meliota G, Buta F, Speziale G. Ivabradine improves quality of life in subjects with chronic heart failure compared to treatment with β-blockers: results of a multicentric observational APULIA study. Pharmacology. 2013;92:276–80.

    Article  CAS  PubMed  Google Scholar 

  12. Sargento L, Satendra M, Longo S, et al. Heart rate reduction with ivabradine in patients with acute decompensated systolic heart failure. Am J Cardiovasc Drugs. 2014;14(3):229–35.

    CAS  PubMed  Google Scholar 

  13. Di Franco A, Sarullo FM, Salerno Y, Figliozzi S, Parrinello R, Di Pasquale P, Lanza GA. Beta-blockers and ivabradine in chronic heart failure: from clinical trials to clinical practice. Am J Cardiovasc Drugs. 2014;14:101–10.

  14. Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K, for the INITIATIVE investigators. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26(23):2529–36.

  15. Tardif JC, Ponikowski P, Kahan T, for the ASSOCIATE study investigators. Efficacy of the I f current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J. 2009;30(5):540–8.

  16. Fox K, Ford I, Steg G, Tendera M, Ferrari R, for the BEAUTIFUL investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372(9641):807–16.

  17. Fox K, Ford I, Steg PG, Tardif M, Ferrari R, for the SIGNIFY investigators. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014;371(12):1091–9.

  18. Schulze V, Steiner S, Hennersdorf M, Strauer BE. Ivabradine as an alternative therapeutic trial in the therapy of inappropriate sinus tachycardia: a case report. Cardiology. 2008;110:206–8.

    Article  CAS  PubMed  Google Scholar 

  19. Retegui G, Quintero M, Ruiz-Borrell M, Revello A. Ivabradine as a treatment option for inappropriate sinus tachycardia. Rev Esp Cardiol. 2009;62:576–88.

    Article  Google Scholar 

  20. Winum P-F, Cayla G, Rubini M, Beck L, Messner-Pellenc P. A case of cardiomyopathy induced by inappropriate sinus tachycardia and cured by ivabradine. PACE. 2009;32:942–4.

    Article  PubMed  Google Scholar 

  21. Settle A, Martino A, Lioy E, Calo L. Efficacy of ivabradine in a case of inappropriate sinus tachycardia and ventricular dysfunction. J Cardiovasc Electrophysiol. 2010;21:815–7.

    Google Scholar 

  22. Goyal VK, Godara S, Sadasukhi TC, Gupta HL. Management of inappropriate sinus tachycardia with ivabradine in a renal transplant recipient. Drug Discov Ther. 2014;8:132–3.

    Article  Google Scholar 

  23. Kaplinsky E, Comes FP, Urondo LSV, Ayma FP. Efficacy of ivabradine in four patients with inappropriate sinus tachycardia: a three month-long experience based on electrocardiographic, Holter monitoring, exercise tolerance and quality of life assessments. Cardiol J. 2010;17:166–71.

    PubMed  Google Scholar 

  24. Calo L, Rebecchi M, Sette A, Martino A, de Ruvo E, Sciarra L, De Luca L, Zuccaro LM, Giunta G, Ciccaglioni A, Lioy E, Fedele F. Efficacy of ivabradine administration in patients affected by inappropriate sinus tachycardia. Heart Rhythm. 2010;7:1318–23.

    Article  PubMed  Google Scholar 

  25. Benezet-Mazuecos J, Rubio JM, Farre J, Quinones MA, Sanchez-Borque P, Macia E. Long-term outcomes of ivabradine in inappropriate sinus tachycardia patients: appropriate efficacy or inappropriate patients. PACE. 2013;36:830–6.

    Article  PubMed  Google Scholar 

  26. Ptaszynski P, Kaczmarek K, Ruta J, Klingenheben T, Wranicz JK. Ivabradine in the treatment of inappropriate sinus tachycardia in patients after successful radiofrequency catheter ablation of atrioventricular node slow pathway. PACE. 2013;36:42–9.

    Article  PubMed  Google Scholar 

  27. Boeken U, Assmann A, Mehdiani A, Akhyari P, Lichtenberg A. Ivabradine in patients with inappropriate sinus tachycardia after cardiac surgery: alternative to β-blockers? Thorac Cardiovasc Surg. 2012;60:119.

  28. Cappato R, Castelvecchio S, Ricci C, Bianco E, Vitali-Serdoz L, Gnecchi-Ruscone T, et al. Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: a prospective, randomized, placebo-controlled, double-blind, crossover evaluation. J Am Coll Cardiol. 2012;60:1323–9.

    Article  CAS  PubMed  Google Scholar 

  29. Ptaszynski P, Kaczmarek K, Ruta J, Klingenheben T, Wranicz JK. Metoprolol succinate vs. ivabradine in the treatment of inappropriate sinus tachycardia in patients unresponsive to previous pharmacological therapy. Europace. 2013;15:116–21.

    Article  PubMed  Google Scholar 

  30. Ptaszynski P, Kaczmarek K, Ruta J, Klingenheben T, Cygankiewicz I, Wranicz JK. Ivabradine in combination with metoprolol succinate in the treatment of inappropriate sinus tachycardia. J Cardiovasc Pharmacol Ther. 2013;18:338–44.

    Article  CAS  PubMed  Google Scholar 

  31. Sheldon RS, Grubb BP II, Olshansky B, Shen W-K, Calkins H, Brignole M, et al. 2015 Heart Rhythm Society Expert Consensus Statement on the Diagnosis and Treatment of Postural Tachycardia Syndrome, Inappropriate Sinus Tachycardia, and Vasovagal Syncope. Heart Rhythm. 2015;12:e41–63.

    Article  PubMed  Google Scholar 

  32. Raj SR. Postural tachycardia syndrome (POTS). Circulation. 2013;127:2336–42.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Ewan V, Norton M, Newton JL. Symptom improvement in postural orthostatic tachycardia syndrome with the sinus node blocker ivabradine. Europace. 2007;9:1202.

    Article  PubMed  Google Scholar 

  34. Hersi AS. Potentially new indication of ivabradine: treatment of a patient with postural orthostatic tachycardia syndrome. Open Cardiovasc Med 2010;4:166–7.

  35. McDonald C, Frith JJL, Newton JL. Single centre experience of ivabradine in postural orthostatic tachycardia syndrome. Europace. 2011;13:427–30.

  36. Sutton R, Salukhe T. Ivabradine in the treatment of orthostatic intolerance. Europace. 2011;13:306–7.

    Article  PubMed  Google Scholar 

  37. Karas B, Grubb BP, Boehm K, Kip K. The postural orthostatic tachycardia syndrome: a potentially treatable cause of chronic fatigue, exercise intolerance, and cognitive impairment in adolescents. Pacing Clin Electrophysiol. 2000;23:344–51.

    Article  CAS  PubMed  Google Scholar 

  38. Kockova R, Svatunkova J, Novotny J, Hejnova L, Ostadal B, Sedmera D. Heart rate changes mediate the embryotoxic effect of antiarrhythmic drugs in the chick embryo. Am J Physiol Heart Circ Physiol. 2013;304:H895–902.

    Article  CAS  PubMed  Google Scholar 

  39. Cademartiri F, Mollet NR, Runza G, Belgrano M, Malagutti P, Meijboom BW, Midiri M, Feyter PJ, Krestin GP. Diagnostic accuracy of multislice computed tomography coronary angiography is improved at low heart rates. Int J Cardiovasc Imaging. 2006;22:101–5.

    Article  PubMed  Google Scholar 

  40. Abbara S, Arbab-Zadeh A, Callioster TQ, Desai MY, Mamuya W, Thomson L, Weigold WG. SCCT guidelines for performance of coronary computed tomographic angiography: a report of the Society of Cardiovascular Computed Tomography Guidelines Committee. J Cardiovasc Comput Tomogr. 2009;3:190–204.

    Article  PubMed  Google Scholar 

  41. Pichler P, Pichler-Cetin E, Vertesich M, Mendel H, Sochor H, Dock W, Syeda B. Ivabradine versus metoprolol for heart rate reduction before coronary computed tomography angiography. Am J Cardiol. 2012;109:169–73.

    Article  CAS  PubMed  Google Scholar 

  42. Celik O, Atasoy MM, Ertürk M, Yalçin AA, Aksu HU, Diker M, Artürk FI, Atasoy I. Single dose ivabradine versus intravenous metoprolol for heart rate reduction before coronary computed tomography angiography (CCTA) in patients receiving long-term calcium channel-blocker therapy. Acta Radiol. 2014;55:676–81.

    Article  CAS  PubMed  Google Scholar 

  43. Guaricci AI, Schuijf JD, Cademartiri F, Brunetti ND, Montrone D, Maffei E, Tedeschi C, Ieva R, Di Biase L, Midiri M, Macarini L, Di Biase M. Incremental value and safety of oral ivabradine for heart rate reduction in computed tomography coronary angiography. Int J Cardiol. 2012;156:28–33.

    Article  PubMed  Google Scholar 

  44. Guaricci AI, Maffei E, Brunetti ND, Montrone D, Di Biase L, Tedeschi C, Gentile G, Macarini L, Midiri M, Cademartiri F, Di Biase M. Heart rate control with oral ivabradine in computed tomography coronary angiography: a randomized comparison of 7.5 mg vs 5 mg regimen. Int J Cardiol. 2013;168:362–8.

    Article  PubMed  Google Scholar 

  45. Celik O, Atasoy MM, Ertürk M, Yalçin AA, Aksu HU, Diker M, Artürk FI, Erkanli K, Atasoy I, Kiris A. Comparison of different strategies of ivabradine premedication for heart rate reduction before coronary computed tomography angiography. J Cardiovasc Comput Tomogr. 2014;8:77–82.

    Article  PubMed  Google Scholar 

  46. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazne MH, Filippatos G, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. J Am Coll Cardiol. 2016. doi:10.1016/j.jacc.2016.05.011.

    PubMed  Google Scholar 

  47. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJV, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WHW, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:e240–327.

    Article  PubMed  Google Scholar 

  48. Cocco G, Jerie P. Comparison between ivabradine and low-dose digoxin in the therapy of diastolic heart failure with preserved left ventricular systolic dysfunction. Clin Pract. 2013;3:e29.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumbholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. N Engl J Med. 1997;336:525–33.

    Article  Google Scholar 

  50. Martin RIR, Pogoryelova O, Santibáñex Koreg M, Bourke JP, Teare MD, Keavney BD. Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomized controlled trials. Heart. 2014;100:1506–10.

  51. Suenari K, Chengg CC, Chen YC, Lin YK, Nankano Y, Kihara Y, Chen SA, Chen YJ. Effects of ivabradine on the pulmonary vein electrical activity and modulation of pacemaker currents and calcium homeostasis. J Cardiovasc Electrophysiol. 2012;23:200–6.

    Article  PubMed  Google Scholar 

  52. Haissagueree M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, Garrique S, Le Mouroux A, Le Métayer P, Clémenty J. Spontaneous initiation of atrial fibrillation by ectopic beats originating in pulmonary veins. N Engl J Med. 1998;339:659–66.

    Article  Google Scholar 

  53. Verrier RL, Bonatti R, Silva AF, Batatinha JA, Nearing BD, Liu G, Rajamani S, Zeng D, Belardinelli L. If inhibition in the atrioventricular node by ivabradine causes rate-dependent slowing of conduction and reduces ventricular rate during atrial fibrillation. Heart Rhythm. 2014;11:2288–96.

    Article  PubMed  Google Scholar 

  54. Kosiuk J, Oebel S, John S, Hilbert S, Hindricks G, Bollmann A. Ivabradine for rate control in atrial fibrillation. Int J Cardiol. 2015;179:27–8.

    Article  PubMed  Google Scholar 

  55. Giuseppe C, Chiara F, Giuseppe R, Maurizio V. Addition of ivabradine to betablockers in patients with atrial fibrillation: effects on heart rate and exercise tolerance: Int J Cardiol. 2016;202:73–4.

    PubMed  Google Scholar 

  56. Abdel-Salam Z, Nammas W. Atrial fibrillation after coronary artery bypass surgery: can ivabradine reduce its occurrence? J Cardiovasc Electrophysiol. 2016;27:670–6.

    Article  PubMed  Google Scholar 

  57. January CT, Wann LS, Alpert JS, Calkins H, Cleveland JC, Cigarroa JE, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):2071–104.

    Article  PubMed  Google Scholar 

  58. Doesch AO, Celik S, Ehlermann P, Frankenstein L, Zehelein J, Koch A, Katus HA, Dengler TJ. Heart rate reduction after heart transplantation with beta-blocker versus the selective If channel antagonist ivabradine. Transplantation. 2007;84:988–96.

    Article  CAS  PubMed  Google Scholar 

  59. Zhang R, Bobylev, Stiefel P, Haverich A, Bara C. Lasting reduction of heart transplant tachycardia with ivabradine is effective and well tolerated: results of 48-month study. Clin Res Cardiol. 2012;101:631–6.

  60. Parakh N, Caturvedi V, Kurian S, Tyagi S. Effect of ivabradine vs atenolol on heart rate and effort tolerance in patients with mild to moderate mitral stenosis and normal sinus rhythm. J Card Fail. 2012;18:282–8.

    Article  CAS  PubMed  Google Scholar 

  61. Saggu DK, Narain VS, Dwivedi SK, Sethi R, Chandra S, Puri A, Saran PK. Effect of ivabradine on heart rate and duration of exercise in patients with mild-to-moderate mitral stenosis: a randomized comparison with metoprolol. J Cardiovasc Pharmacol. 2015;65:552–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Roubille F, Lattuca B, Busseuil D, Leclercq F, Davy JM, Rhéaume E, Tardif JC. Is ivabradine suitable to control undesirable tachycardia induced by dobutamine in cardiogenic shock treatment? Med Hypotheses. 2013;81:202–6.

    Article  CAS  PubMed  Google Scholar 

  63. Cavusoglu Y, Mert U, Nadir A, Mutlu F, Morrad B, Ulus T. Ivabradine treatment prevents dobutamine-induced increase in heart rate in patients with acute decompensated heart failure. J Cardiovasc Med. 2015;16:603–9.

    Article  CAS  Google Scholar 

  64. Clinical Trials.gov. Protocol NCT02247245. The influence of heart rate limitation on exercise tolerance in pacemaker patients. (TREPPE). https://clinicaltrials.gov/ct2/show/NCT02247245?term=ivabradine&rank=35. Accessed 3 Jun 2016.

  65. Clinical Trials.gov. Protocol NCT02236247. Control of sinus node tachycardia as an additional therapy in patients with decompensated heart failure (CONSTATHE). https://clinicaltrials.gov/ct2/show/NCT02236247?term=ivabradine&rank=29. Accessed 3 Jun 2016.

  66. Clinical Trials.gov. Protocol NCT01868880. Effect of ivabradine and beta-blockers combination versus beta-blockers up-titration on right ventricular pacing. https://clinicaltrials.gov/ct2/show/NCT01868880?term=ivabradine&rank=19. Accessed 3 Jun 2016.

Download references

Author information

Authors and Affiliations

  1. Methodist University Hospital, 1265 Union Avenue, Memphis, 38104, TN, USA

    Carrie S. Oliphant & Ryan E. Owens

  2. College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN, USA

    Carrie S. Oliphant

  3. College of Medicine, University of Tennessee Health Science Center, Memphis, TN, USA

    Oluwaseyi B. Bolorunduro & Sunil K. Jha

Authors
  1. Carrie S. Oliphant
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ryan E. Owens
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Oluwaseyi B. Bolorunduro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sunil K. Jha
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carrie S. Oliphant.

Ethics declarations

Funding

No external funding was used in the preparation of this manuscript.

Conflict of interest

Carrie Oliphant, Ryan Owens, Oluwaseyi Bolorunduro, and Sunil Jha have no conflicts of interest that might be relevant to the contents of this manuscript.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Oliphant, C.S., Owens, R.E., Bolorunduro, O.B. et al. Ivabradine: A Review of Labeled and Off-Label Uses. Am J Cardiovasc Drugs 16, 337–347 (2016). https://doi.org/10.1007/s40256-016-0178-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40256-016-0178-z

Keywords

Search

Navigation